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Hypertriglyceridemia is not only a serious risk factor in the development of cardiovascular
diseases, but it is linked to neurodegeneration, too. Previously, we generated transgenic
mice overexpressing the human APOB-100 protein, a mouse model of human
atherosclerosis. In this model we observed high plasma levels of triglycerides, oxidative
stress, tau hyperphosphorylation, synaptic dysfunction, cognitive impairment, increased
neural apoptosis and neurodegeneration. Neurovascular dysfunction is recognized as
a key factor in the development of neurodegenerative diseases, but the cellular and
molecular events linking cerebrovascular pathology and neurodegeneration are not fully
understood. Our aim was to study cerebrovascular changes in APOB-100 transgenic
mice. We described the kinetics of the development of chronic hypertriglyceridemia
in the transgenic animals. Increased blood-brain barrier permeability was found in the
hippocampus of APOB-100 transgenic mice which was accompanied by structural
changes. Using transmission electron microscopy, we detected changes in the brain
capillary endothelial tight junction structure and edematous swelling of astrocyte
endfeet. In brain microvessels isolated from APOB-100 transgenic animals increased
Lox-1, Aqp4, and decreased Meox-2, Mfsd2a, Abcb1a, Lrp2, Glut-1, Nos2, Nos3,
Vim, and in transgenic brains reduced Cdh2 and Gfap-σ gene expressions were
measured using quantitative real-time PCR. We confirmed the decreased P-glycoprotein
(ABCB1) and vimentin expression related to the neurovascular unit by immunostaining
in transgenic brain sections using confocal microscopy. We conclude that in chronic
hypertriglyceridemic APOB-100 transgenic mice both functional and morphological
cerebrovascular pathology can be observed, and this animal model could be a useful
tool to study the link between cerebrovascular pathology and neurodegeneration.
Keywords: apolipoprotein B-100, astroglia, blood-brain barrier, brain endothelial cell, cerebrovascular pathology,
hypertriglyceridemia, P-glycoprotein, tight junction
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INTRODUCTION
There is growing preclinical and clinical evidence that
pathological changes at the level of the neurovascular unit
(NVU), comprising all the cell types of cerebral microvessels
and the surrounding neural tissue, lead to secondary neuronal
injury and neurodegenerative diseases, including Alzheimer’s
disease (AD) (Zhao et al., 2015). The key pathways of vascular
dysfunction that are linked to neurodegenerative diseases include
blood-brain barrier (BBB) breakdown, hypoperfusion-hypoxia
and endothelial metabolic dysfunction (Zlokovic, 2008; Zhao
et al., 2015). Morphologically the BBB is formed by the capillary
endothelium, the basement membrane and the surrounding
pericytes and astrocytic endfeet. The endothelial cells adhere
tightly to one another, through junctional structures termed
tight junctions (TJs), which restrict paracellular permeability
of the BBB [3]. Several families of active influx and eﬄux
transporters and transcytotic receptor systems regulate the
exchange of small and large nutrients and metabolites across
the BBB (Zlokovic, 2008). Both the structure and functions
of the BBB are damaged in AD: the barrier function of TJs is
impaired, the energy supply of neural cells is decreased, the
entry of neurotoxic agents is elevated and the clearance of Aβ
peptides is reduced (Zlokovic, 2008, 2011; Lyros et al., 2014; Di
Marco et al., 2015; Zhao et al., 2015). Many studies suggest a
direct link of atherosclerosis with not only vascular, but also AD
dementia, although the relationship is still unclear (Nelson et al.,
2016; Kapasi and Schneider, 2016). NVU and BBB pathologies
have been increasingly investigated in genetic and other animal
models of AD (Nicolakakis and Hamel, 2011), but there are very
few models focusing on the link between atherosclerosis and
dementia (Li et al., 2003; Lane-Donovan et al., 2016) or NVU
changes.
Previously, we generated a mouse model of human
atherosclerosis using transgenic mice overexpressing the
human APOB-100 protein in different tissues such as the liver,
heart and brain (Bjelik et al., 2006; Csont et al., 2007; Lénárt et al.,
2012). Apolipoprotein B-100 (APOB-100) is a large, 512 kDa
glycoprotein that circulates in the plasma as the major protein
component of low density lipoprotein (LDL) and very low
density lipoproteins (VLDL). The higher ratio of LDL and VLDL
fractions compared to HDL in the blood of these transgenic
animals is similar to the human plasma lipoprotein profile,
therefore this mouse strain is more suitable to study the effects
of hypercholesterinaemia and hypertriglyceridemia than the
wild-type mice (Csont et al., 2007). Several studies have shown
that the concentration of APOB is elevated in the serum of
AD patients (Caramelli et al., 1999; Sabbagh et al., 2004) which
correlates with β-amyloid (Aβ) deposition in AD brains (Kuo
et al., 1998). Cholesterol and apolipoprotein accumulates in
mature amyloid plaques in brains from both AD patients and
animal models of AD (Puglielli et al., 2003). The processing of
amyloid precursor protein (APP) is modulated by cholesterol
which is enriched in the membrane microdomains of neurons
(Ehehalt et al., 2003). The amount of 24S-hydroxycholesterol
is increased in the plasma of AD and vascular dementia
patients, indicating a change in the metabolism of cholesterol
(Lutjohann et al., 2000). High levels of plasma triglyceride
preceded the formation of amyloid plaques in transgenic mouse
models of AD (Burgess et al., 2006). In our model, APOB-100
transgenic mice showed significantly elevated serum triglyceride
and cholesterol level when fed with normal chow and cholesterol
rich diet, respectively (Csont et al., 2007), and increased the
rigidity of the plasma membrane of brain endothelial cells
isolated from these transgenic animals (Lénárt et al., 2015). In the
past 10 years we have described in detail the neurodegenerative
processes occurring in the brain of hypertriglyceridemic
APOB-100 transgenic mice. We detected widespread neuronal
cell death and apoptosis of cortical and hippocampal neurons
in this model (Lénárt et al., 2012). Synaptic dysfunction in
the hippocampal region of APOB-100 transgenic mice using
electrophysiolology and hyperphosphorylation of the tau protein
(primarily at Ser262, Ser396, Ser199/202, Ser404phosphosites)
were also shown (Lénárt et al., 2012). As a consequence of the
extended neurodegeneration a pronounced enlargement of
brain ventricles in transgenic brains was detected using MRI,
which was transgene dose-dependent (Bereczki et al., 2008).
Moreover, APOB-100 overexpression increased the level of
lipid peroxidation in cortical and hippocampal brain regions
and impaired cognitive function of the animals (Löﬄer et al.,
2013).
Under cerebral ischemic conditions, decreased cortical
microvascular density and increased brain capillary lumen
diameter was found in our APOB-100 transgenic atherosclerosis
model showing neurodegeneration (Süle et al., 2009). Cerebral
ischemia also promoted the swelling of perivascular astrocytes
and reduced the ratio of intact capillaries (Süle et al., 2009). Our
aim was to further study neurovascular pathology and reveal
structural and functional changes in the BBB of APOB-100
transgenic mice that may contribute to the neurodegeneration
already described in this model.
MATERIALS AND METHODS
Animals
All animals were handled in accordance with approved
procedures as defined by the EU Directive 2010/63/EU and all
animal work was approved by the regional Station for Animal
Health and Food Control (Csongrád-county, Hungary; project
license: XVI/4136/2014). Mice were housed in groups of two
to three under standard conditions (24◦C, 12 h light–dark
cycle) with food and water available ad libitum. APOB-100
transgenic mice were produced in our laboratory as described
previously (Bjelik et al., 2006). Transgenic mice were backcrossed
with C57B/6 strain six times to achieve a homogenous genetic
background. Animals were maintained on a regular rodent
chow diet. Animal surgeries were performed under sodium
pentobarbital (Nembutal) anesthesia and all efforts were made
to minimize pain and suffering. For genotyping, tail DNA of
10-day-old pups was purified as described earlier (Bjelik et al.,
2006) and integrated transgenes were detected by PCR, using
primers from the 5′ promoter region of the human APOB gene
(Callow et al., 1994).
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 October 2018 | Volume 12 | Article 380
fncel-12-00380 October 24, 2018 Time: 15:40 # 3
Hoyk et al. Cerebrovascular Pathology in APOB-100 Mice
Materials
All reagents were purchased from Sigma-Aldrich Ltd. (St. Louis,
MO, United States) except for those specifically mentioned.
Serum Triglyceride Measurement
Serum triglyceride levels in 7, 9, and 12-month-old APOB-100
transgenic (n = 5) and wild-type mice (n = 5) fed on a
normal chow diet were measured using a colorimetric assay
(Supplementary Table S1). Blood samples were collected
through cardiac puncture under terminal anesthesia. After
clot formation samples were centrifuged at 4◦C, 1000 × g
for 10 min, then serum was removed and stored at −80◦C
until use. Serum triglyceride levels were measured in triplicate
using a commercially available enzymatic colorimetric assay
kit (Diagnosticum Ltd., Budapest, Hungary) according to
the manufacturer’s instructions. Test accuracy was monitored
using Standard Lipid Controls (Diagnosticum Ltd., Budapest,
Hungary). Absorbance of the produced purple color product
was measured at 560 nm using a microplate reader (Multiskan
FC, Thermo Scientific, United States). Values were expressed in
mmol/liter. Experimental groups, (APOB-100 transgenic mice
and wild-type littermates) consisted of 5 animals each.
BBB Permeability
Permeability for sodium fluorescein (SF, mw: 376 Da), a marker
of paracellular flux, and Evans blue (EB, mw: 67 kDa), a
tracer which binds to serum albumin (Patterson et al., 1992),
was measured as described in detail earlier (Veszelka et al.,
2003). Six-month-old wild-type and transgenic mice (n = 10
animals/group) (Supplementary Table S1) were given a solution
of both dyes (2%, 5 ml/kg) in an iv. injection to the tail
vein for 1 h, and at the end of the experiments, the animals
were perfused with 25 ml phosphate-buffered saline (PBS) for
15 min. Samples from two brain regions, cerebral cortex and
hippocampus, were collected, weighed and stored at −80◦C.
Tissue pieces were homogenized in 650 µl PBS, then 650 µl of
cold, 50% w/v, freshly prepared trichloroacetic acid was added
and samples were centrifuged again with 10,000 × g for 12 min
at 4◦C. Dye concentrations were measured in supernatants by a
PTI spectrofluorimeter (T-format, Quanta Master QM-1; Photon
Technology International). Five hundred µl of the supernatants
were diluted in ethanol (1:3) than emission of Evans blue was
measured at 650 nm after excitation at 600 nm wavelength. For SF
measurement 500 µl supernatants were diluted in distilled water
(1:3) then 100 µl 10N NaOH was added to each sample. Emission
of fluorescein was measured at 510 nm after excitation at 492 nm
wavelength. BBB permeability was expressed as ng tracer/g brain
tissue.
Transmission Electron Microscopy (TEM)
and Image Analysis
Seven-month-old wild-type and transgenic mice (n = 4
animals/group) (Supplementary Table S1) were anesthetized
with sodium pentobarbital (150 µg/g, i.p.), then transcardially
perfused with 0.9% NaCl in 0.01 M phosphate buffer
(PB), followed by 4% paraformaldehyde containing 2.5%
glutaraldehyde in 0.1 M PB. Brains were removed and post-fixed
in 4% paraformaldehyde in 0.1 M PB overnight at 4◦C. Then,
40-µm-thick coronal sections were cut on an Oxford Vibratome
(The Vibratome Company, St. Louis, MO, United States).
Sections were washed with PBS and incubated in 1% OsO4
for 30 min, then rinsed with distilled water and dehydrated
in graded ethanol, block-stained with 1% uranyl acetate in
50% ethanol for 30 min and embedded in Taab 812 (Taab;
Aldermaston, United Kingdom). Following polymerization
at 60◦C for 12 h, 60–70 nm ultrathin sections were cut using
a Leica UCT ultramicrotome (Leica Microsystems, Milton
Keynes, United Kingdom) and examined using a Hitachi
7100 transmission electron microscope (Hitachi Ltd., Tokyo,
Japan). Electron micrographs were made by Veleta 2k × 2k
MegaPixel side-mounted TEM CCD camera (Olympus, Tokyo,
Japan). Contrast/brightness of electron micrographs was edited
by Adobe Photoshop CS3 (Adobe Photoshop Inc., San Jose,
CA, United States). Altogether 215 non-overlapping images
representing 56 capillaries from the frontal cortex and 111
non-overlapping images representing 59 capillaries from
the hippocampus were analyzed for morphological changes.
All analyzed images were taken at 30,000× magnification.
To calculate pericyte coverage on capillary profiles, the
circumference of brain endothelial cells at their abluminal
side facing the basal membrane was marked manually by a
line with one color, and the length of pericytes with another.
Only pericyte branches completely embedded in the capillary
basement membrane were counted. The length of the lines was
determined by Matlab. The background (the original image) was
removed and the two colors were seperated to two channels.
The pixel number of the two differently labeled lines is a good
approximation of the pericyte to brain capillary endothelial
circumference in each group. Thus, the ratio of the structures is
the ratio of the two cumulative pixel numbers.
Brain Microvessel Isolation
Cortical microvessels were isolated from the brain of
6–7-month-old animals, as described earlier (Veszelka et al.,
2007). The forebrains of APOB-100 overexpressing or wild-type
mice (n = 6) (Supplementary Table S1) were collected in ice-cold
sterile phosphate buffered saline (PBS). Meninges were taken
off by rolling brains on a sterile wet filter paper. White matter
and the choroid plexus were removed and the tissue was minced
into 1 mm3 pieces by scalpels. Samples then were homogenized
in ice-cold Ringer-Hepes buffer (4 ml/g of tissue), and the
resulting homogenates were centrifuged at 1000 g for 10 min.
After centrifugation the microvessel enriched pellets were
resuspended in 17.5% dextran (64–76 kDa) in Ringer-Hepes, and
centrifuged at 4◦C, 1500 × g for 15 min. The resulting pellets
were suspended in 2 ml Ringer-Hepes buffer containing 1% BSA,
while the supernatants were collected and centrifuged two more
times. The resulting pellets were pooled and passed through a
100 µm and a 20 µm nylon mesh. The microvessels retained
by the 20 µm mesh were washed off with 10 ml buffer and
centrifuged at 4◦C, 1000 g for 10 min. Finally, the pellets were
resuspended in 1 ml buffer and centrifuged at 4◦C, 10,000 g for
2 min, and stored in TRIZOL reagent until use. A small aliquot
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of the brain microvessel preparation was observed with phase
contrast microscopy, and similarly to our previously published
data (Veszelka et al., 2007), these fractions only contained brain
microvessel endothelial cells and pericytes.
Quantitative Real-Time PCR
Total RNA was extracted from primary cell cultures, cortical
microvessel samples, or hippocampal and cortical brain regions
using TRIZOL reagent according to the manufacturer’s protocol.
Hippocampal and cortical brain samples were derived from
6-month-old mice (n = 6 animals/group) (Supplementary
Table S1). Briefly, samples were homogenized in the appropriate
volume of TRIZOL reagent, then 1/5 volume chloroform was
added to each mixture and the samples were incubated on ice
for 5 min. After centrifugation at 12,000 × g for 15 min at
4◦C, the RNA containing aqueous phase was separated from the
organic phase. The RNA was precipitated with 100% isopropyl
alcohol and incubated for 10 min at −20◦C. After centrifugation
for 10 min at 12,000 × g at 4◦C, RNA was washed with 80%
ethanol and samples were centrifuged for 5 min at 12,000 × g
at 4◦C. RNA pellets were dissolved in RNase free water and then
bound to RNA Clean Up column (NucleoSpin RNA clean-up kit,
Macherey-Nagel) where they were treated with DNase. RNA was
finally eluted from the membrane with RNase-free water, and the
concentrations of the samples were measured at 230 nm using a
spectrophotometer (NanoDrop ND-1000).
mRNA samples were converted to cDNA by using a reverse
transcriptase kit (High Capacity cDNA Reverse Transcription
Kit, Applied Biosystems). Each reaction mix consisted of 2 µg
RNA (15 µl); 1.5 µl reverse transcriptase; 3 µl primer; 1.2 µl
dNTP; 3 µl buffer; 6.3 µl RNase free water. The temperature
profile of the reaction was the following: 10 min at 25◦C,
2 h at 37◦C and 5 min at 85◦C (using MJ Mini - Personal
Thermal Cycler, BioRad). The cDNA was finally diluted 1:20,
and 9 µl of this mix was used as a template in the PCR
reaction that follows. Each reaction was performed in a total
volume of 20 µl containing 10 µl of 2x Power SYBR Green PCR
Master Mix (Applied Biosystems), 1 µl of 5 pmol/µl primer mix
(forward+ reverse) and 9 µl of cDNA sample. The amplification
was carried out on a RotorGene 3000 instrument (Corbett
Research) with the following cycling parameters: heat activation
at 95◦C for 10 min; followed by 45 cycles of denaturation at
95◦C for 15 s, annealing at 56◦C for 15 s, and extension at
60◦C for 40 s in 45 cycles. Fluorescent signals were collected
after each extension step at 72◦C and at the end the registration
of the melting curve was performed between 50 and 95◦C.
The expression level of target genes was normalized to an
endogenous control gene Gapdh or Actb (1Ct). Then 11Ct
was calculated, i.e., the relative expression of the target genes
in transgenic animals was compared with the expression levels
observed in wild-type animals. Fold-differences were calculated
using the 2−11Ct formula and were expressed in percents.
Gene expression changes were considered significant if the
expression level dropped below 50% or showed a two-fold
increase compared with control values. We studied genes
involved in different molecular mechanism, such as oxidative
stress, transport pathways or endothelial dysfunction. Individual
genes were selected based on literature data, especially those
identified in BBB transcriptome analysis in mice (Daneman et al.,
2010), related to AD pathology (Wu et al., 2005), or selected
for our recently published gene expression analysis of different
BBB models (Veszelka et al., 2018). Primer sequences used in this
study are listed in Supplementary Table S2.
Immunohistochemistry and Confocal
Microscopy
Standard immunofluorescence protocols were applied. 7–8-
months-old mice (Supplementary Table S1) were terminally
anesthetized with sodium pentobarbital (150 µg/g, i.p.), then
transcardially perfused with 0.9% sodium chloride dissolved in
0.01 M PB, pH 7.4, followed by 3% paraformaldehyde in 0.1 M
PB, pH 7.4. Brains were removed and postfixed for 4 h in the
same fixative. Following fixation the brain samples were washed
in 0.1 M PB, pH 7.4, and cryoprotected in 30% sucrose until
saturation. Then, 30-µm-thick, hippocampus and frontal cortex
containing coronal sections were cut on a cryostat (Floorstanding
Cryostat MNT; Slee, Mainz, Germany), collected in 0.1 M PB, pH
7.4 containing 0.01% sodium azide (Fluka) (w/v) and were stored
at 4◦C.
Antigen retrieving for claudin-5 and occludin
immunostainings was performed with 0.5 % Triton X-100
in PBS for 10 min, followed by an incubation in protease
type XIV (1 µg/ml) dissolved in CaCl2 (1 mg/ml) for 7 min.
Antigen retrieving for the other primary antibodies used
included only Triton X-100 treatment at concentrations based
on our preliminary experiments [0.1% for Pdgfrβ, 0.2% for
vimentin and Gfap, 0.3% for Lox-1, and 0.5% for P-glycoprotein
(Pgp) for details of Lox-1 immunolabeling see Supplementary
Material]. Primary antibodies used were rabbit anti-claudin-
5, rabbit anti-occludin (Thermo Fisher Scientific, Waltham,
MA, United States), goat anti-Gfap (Abcam, Cambridge,
United Kingdom), mouse anti-vimentin [Agilent (DAKO), Santa
Clara, CA, United States], mouse anti-Pgp (Merck Millipore,
Burlington, MA, United States), and rabbit anti Lox-1 (Abcam,
Cambridge, United Kingdom), (Supplementary Table S3).
Appropriate secondary antibodies conjugated with DyLightTM
488 and Alexa FluorTM 594 (Jackson ImmunoResearch Europe
Ltd., Cambridgeshire, United Kingdom) were applied. Sections
were counterstained with DAPI, coverslipped with Confocal
Matrix R© (Micro Tech Lab, Graz, Austria) and examined with
a confocal laser scanning microscope (Olympus Fluoview
FV1000, Olympus Life Science Europa GmbH, Hamburg,
Germany). Images of 512 × 512 px were captured using the
following microscope configuration: objective lens: UPLSAPO
60x, numeric aperture 1.35; sampling speed: 8 µs/pixel; scanning
mode: sequential unidirectional. In order to obtain high
resolution (1024 × 1024 px) images, Yokogawa W1/Olympus
IX83-based spinning disk confocal microscope was also used
for imaging Gfap, vimentin, and Pdgfrβ immunostainings
using excitation and detection parameters optimized for
DyLightTM 488, Alexa FluorTM 594 and DAPI. 405nm (for
DAPI), 488 nm (for DyLightTM 488) and 561 nm (for Alexa
FluorTM 594) laser excitation, and 60x objective were used
for imaging. The contrast of these images showing Gfap
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immunostaining was increased by inverting and displaying
them as gray scale images using the public domain Fiji
software.
Fluorescence Intensity Analysis
Immunostained coronal sections containing the hippocampus
and cortical areas (5 animals per group, 3 sections per animal)
were selected based on the principle of systematic random
sampling (Gundersen and Osterby, 1981; Mayhew, 1991). Three
images representing randomly selected parts of the hippocampus
and frontal cortex in each section were taken with a laser
scanning (for claudin-5, occludin and Pgp immunolabeling) or
a spinning disk (for Gfap immunostaining) confocal microscope
using a 60× objective lens and the same excitation and detection
parameters for each image. Fluorescence intensity of claudin-5,
occludin and Pgp immunolabelings was evaluated using the
ImageQuantTM software as follows: on every image 10 equally
sized small rectangular areas (7× 7 pixels) were placed randomly
on the intensively highlighted immunolabeled structures, and
five equal rectangles were placed randomly on areas lacking
immunostaining representing the background. Then the average
intensity/pixel values of each area were calculated, and the
average intensity/pixel values representing the background
intensity were subtracted from those of immunolabeled areas.
The GFAP immunostained structures represented a more a
complex pattern and occupied larger areas, therefore the
integrated fluorescence intensity of Gfap immunolabeling was
measured using the public domain Fiji software as follows:
Grayscale 16-bit images were used. The integrated fluorescence
intensity of the whole image and that of a small area lacking
immunostained structures were measured, then the background
fluorescence intensity of the whole image was calculated and
subtracted from the integrated fluorescence intensity value of the
whole image. The procedures were performed on each image, and
the collected data were statistically analyzed (Farkas et al., 2008).
Statistical Analysis
GraphPad Prism 5.0 software (GraphPad Software Inc. LaJolla,
CA, United States) was used for statistical analysis. Gaussian
distribution of the data was tested with the Kolmogorov–Smirnov
normality test. Data showing Gaussian distribution were
analyzed with two-way analysis of variance followed by
Bonferroni post hoc test. Data showing no Gaussian distribution
were analyzed with Kruskal–Wallis and Dunn’s multiple
comparison tests. The level of statistical significance was taken
as p < 0.05. Results are presented as means± SEM.
RESULTS
Chronic Hypertriglyceridemia in
APOB-100 Transgenic Mice
A statistically significant difference was detected in transgenic
compared to wild-type animals at every time point (7, 9,
and 12-month, n = 5 animals/group) indicating chronic
hypertriglyceridemia in APOB-100 transgenic mice (Figure 1A).
Impairment of the BBB Integrity:
Permeability Measurements
We measured a significant increase in the BBB permeability
(p < 0.05) for the small molecular weight marker SF in
the hippocampal region of transgenic mice, while alteration
in the extravasation of the large serum protein albumin
showed a non-significant trend (Figure 1B). However, there
was no obvious change in the permeability for either of the
markers in the cortex of transgenic mice compared to wild-type
littermates.
BBB Dysfunction: Changes in Gene and
Protein Expression in Brain Microvessels
Reduced expression (16%) of the vascular restricted and
mesenchyme homeobox gene 2 (Meox2), a key regulator of
BBB functions, particularly in AD, was measured in cerebral
microvessels of APOB-100 transgenic mice compared to
wild-type animals (Figure 1C). The gene expression of
Mfsd2a (44%), the BBB transporter for unsaturated lipid
docosahexaenoic acid (DHA), and the primary glucose
transporter in brain endothelial cells, Glut-1 (57%) were
also decreased (Figure 1C).
Lox-1, a lectin-like protein expressed in endothelial cells in
the periphery is considered as the major receptor for oxidized
low-density lipoprotein. The level of oxidized LDL (oxLDL)
receptor (Lox-1) has increased dramatically (297%) in the
microvessels of APOB-100 transgenic mice (Figure 1C). In
contrast to the periphery, where Lox-1 was detected in heart
coronal vessels, Lox-1 immunolabeling was observed only in
neuronal cell bodies and processes, but not in brain capillaries
(Supplementary Figure S1). A significant increase in Lox-1
immunoreactive area was detected in the cortex, but no change
was seen in the hippocampus of transgenic mice compared to
wild-type animals (Supplementary Figure S2). While mRNA
level of LDL receptor-related protein-1 (Lrp1, 70%) slightly
decreased, the expression level of Lrp2 dropped to 56% in
transgenic microvessels (Figure 1C).
We measured two isoforms of nitric oxide (NO) synthases
(NOS), the endothelial (eNos/Nos3) and the inducible form
(iNos/Nos2), and found a significant decrease for both genes in
brain microvessels of transgenic animals (Figure 1C). Expression
of mRNA for caveolin-1 (Cav-1), a structural element of brain
endothelial caveolae associated with Nos3, was also reduced
(Figure 1C).
The expression of selected TJ proteins was analyzed at
gene expressional level using quantitative real-time PCR, and
at protein level using fluorescence immunohistochemistry, too.
The mRNA level of transmembrane protein Ocln, and TJ
cytoplasmic linker Tjp-1, was reduced to half in transgenic
microvessels, while there was no change in the expression
level of Cldn-5, the dominant claudin member at the BBB,
compared to wild-type animals (100%) (Figure 1C). Fluorescence
immunohistochemical stainings for claudin-5 (Figure 2A) and
occludin (Figure 3A) showed that both immunolabelings
were exclusively localized at endothelial TJs and appeared as
continuous lines. There was no statistically significant change
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FIGURE 1 | Serum triglyceride levels (A), BBB permeability for fluorescein and albumin in the brain of hypertriglyceridemic APOB-100 transgenic (APOB-100) and
wild-type (Wt) mice (B), and gene expression analysis of the microvessel fraction from APOB-100 transgenic mice using QPCR (C). Continuous line indicates the
expression level of the corresponding gene in wild-type mice (100%). Dashed lines indicate the levels of significant changes: a 2 fold (200%) increase or an 0.5 fold
(50%) reduction in gene expression. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05, compared with Wt mice.
neither in claudin-5 nor in occludin immunostaining intensity
in transgenic cortex and hippocampus compared to wild-type
animals (Figures 2B, 3B).
The gene expression of vimentin, a cytoskeletal protein, which
labels reactive astrocytes (Pekny et al., 2007), but can be produced
by pericytes (Bandopadhyay et al., 2001) and brain endothelial
cells (Deracinois et al., 2013) too, showed a significant reduction
in isolated brain microvessels (Figure 1C). At protein level,
vimentin was localized along capillaries in the frontal cortex
of wild-type mice as it can be observed in occludin-vimentin
double immunofluorescence stainings (Figure 3A), where
occludin immunolabeling delineates brain capillaries. Vimentin
immunoreactivity was very rarely seen in the frontal cortex of
APOB-100 transgenic animals, and it was not detected in the
hippocampus of either genotype (Figure 3A). The vimentin
immunolabeling showed no co-localization with epitopes
recognized either by a Gfap antibody (an astroglia marker),
or by a Pdgfrβ antibody (a pericyte marker) (Supplementary
Figure S3). Furthermore, we have established primary pericyte,
astrocyte and endothelial cell cultures from wild-type and
transgenic mice and vimentin gene expression was measured
using QPCR. The vimentin gene expressions normalized
to the endogenous mouse actin gene were compared in
wild-type animals (1CT values). Vimentin was expressed
at high level in endothelial cells (1CT = 1.3), astrocytes
(1CT = 2) and pericytes (1CT = 2.3) as well. Comparison
of the vimentin expression level of wild-type and transgenic
animals demonstrates that while the vimentin expression levels
were not changed significantly in the transgenic endothelial cells
and astrocytes (74 and 124%, respectively) transgenic pericytes
showed significantly reduced vimentin level (33%) compared to
wild-type cells (Supplementary Figure S4). The most widely
studied, and AD related ABC transporter at the BBB, Abcb1 or
P-glycoprotein (P-gp) was also examined by QPCR in isolated
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FIGURE 2 | Claudin-5 immunostaining pattern (red) in the cortex and hippocampus of wild-type (Wt) and APOB-100 transgenic mice (APOB-100), counterstained
with DAPI (blue) (A). Scale bar: 20 µm. Quantification of fluorescence intensity of claudin-5 immunolabeling in the frontal cortex and hippocampus of Wt and
APOB-100 transgenic mice (B).
brain microvessels and by immunohistochemistry in the frontal
cortex and hippocampus of wild-type and APOB-100 transgenic
mice. From the isoforms of P-gp coding genes, Abcb1a mRNA
expression was significantly decreased (51%), while Abcb1b
(138%) showed no significant change (Figure 1C). Using a
monoclonal antibody recognizing both isoforms of P-gp the
immunoreactivity pattern of P-gp was similar to that of TJ
proteins delineating a large number of capillaries in the frontal
cortex and hippocampus in wild-type animals. However, in
the APOB-100 transgenic group, P-gp immunoreactivity could
hardly be observed in either brain region examined (Figure 4A),
which was reflected by a significant drop in P-gp fluorescence
intensity in APOB-100 transgenic mice compared to wild-type
animals in the cortex and hippocampus, too (Figure 4B).
Astroglial endfeet are important structural and functional
elements of the BBB. The gene expression level of aquaporin-4
(Aqp4), a water channel and a marker of glial endfeet, has
increased dramatically (225%) in isolated brain microvessels
(Figure 1C), while no change was observed in brain samples
(Figure 6). In the microvessel samples the glial specific
calcium-binding cytoplasmic protein S100b (129%) and the
astrocyte produced brain derived neurotrophic factor (Bdnf,
123%) levels showed no change (Figure 1C).
Ultrastructural Changes of the BBB in
APOB-100 Transgenic Mice
Analysis of the ultrastructure of brain capillaries using TEM
revealed several alterations in the NVU of APOB-100 transgenic
mice compared to wild-type animals (Figure 5 and Table 1).
The most significant changes were observed in the morphology
of TJs and astrocytic endfeet. Swollen astrocytic processes
around capillaries were predominant in the transgenic group,
indicating edema of glial endfeet (Figure 5A and Supplementary
Figure S5). The intercellular junctions of capillary endothelial
cells were characterized by a continuous electron dense material
in wild-type mice (Figure 5B). In the transgenic group, in
contrast, nearly half of the endothelial cell contacts displayed a
discontinuous electron dense structure (Figure 5B and Table 1).
Further ultrastructural differences include basal membrane
alterations, like increased thickness, tortuosity, fragmentation,
and alterations in luminal membrane characteristics, like
increased number of protrusions in the transgenic group. No
significant difference was found in the pericyte coverage of brain
capillaries (Table 1). The described ultrastructural changes were
detected in the frontal cortex and in the hippocampus as well.
Neuroinflammation and Neuron Related
Changes in the Cortex and Hippocampus
From the genes of selected cytokines and neuroinflammatory
markers the expression of cytokine Tnfα (152%) and the
inflammation related nuclear factor NF-κB (167%) increased in
the transgenic cortex but were not substantially changed in the
hippocampus. No change was measured for Il-1β (Figure 6).
Similarly, there was no notable change in the expression of
other inflammatory markers in the cortex, except for Tlr4, the
expression of which was dropped down to 60%. Of neuronal
synaptic genes, which play an important role in remodeling
CNS synapsis, the level of Nlgn1 (152%) has slightly increased
in the hippocampus but was not changed in the cortex. The
expression level of Nmdar and Nrxn1 was unchanged both
in the hippocampus and in the cortex. However, a significant
decrease in the expression level of a cell adhesion molecule,
Cdh2 (N-cadherin), (32%) was detected in the hippocampus of
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FIGURE 3 | Occludin (red) and vimentin (green) immunostaining pattern in the cortex and hippocampus of wild-type (Wt) and APOB-100 transgenic mice
(APOB-100) counterstained with DAPI (blue) (A). Scale bar: 20 µm. Quantification of fluorescence intensity of occludin immunolabeling in the frontal cortex and
hippocampus of Wt and APOB-100 transgenic mice (B).
transgenic brains (Figure 6). The results of gene expression
analysis are summarized in Table 2.
Out of 600 miRNAs analyzed, we could detect 10 (1.67%)
differentially expressed miRNA genes in APOB100 transgenic
cortices (6 upregulated and 4 repressed). List of miRNA genes
with altered expression level is shown in Supplementary
Table S4. Overexpressed miRNAs were mmu-miR-669g,
mmu-miR-222, mmu-miR-708, mmu-miR-26a, mmu-miR-1898,
and mmu-miR-500, and repressed miRNAs were mmu-miR-7a,
mmu-miR-7b, mmu-miR-187, and mmu-miR-1a. Although
we found 10 miRNAs showing differential expression, only 4
miRNAs had experimentally validated targets in the IPA database
(mmu-miR-1a, mmu-miR-222, mmu-miR-26a, mmu-miR-7b).
Some of these target genes (n = 11) were expected to have
relevance in neuronal changes. The expression level of these
genes was further investigated by QPCR but no significant
changes were detected (data not shown) with the exception of
Bdnf. This gene may be regulated by two differentially expressed
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FIGURE 4 | P-gp (ABCB1) transporter immunostaining pattern (red) in cortical and hippocampal areas of wild-type (Wt) and APOB-100 transgenic mice
(APOB-100), counterstained with DAPI (blue) (A). Scale bar: 20 µm. Quantification of fluorescence intensity of P-gp immunolabeling in the frontal cortex and
hippocampus of Wt and APOB-100 transgenic mice (B) ∗∗∗P < 0.001, ∗P < 0.05, compared with Wt mice.
miRNAs: mmu-miR-26a (overexpressed), and mmu-miR-1a
(repressed). QPCR data showed a two-fold overexpression of
Bdnf gene in the transgenic cortex (Supplementary Figure S6).
Changes in Glial Cell Gene Expression
and Morphology
The expression level of the microglial marker (Iba-1/Aif1) was
slightly increased (145%) in the hippocampus of APOB-100
transgenic mice compared to wild-type animals (Figure 6). In
contrast, the expression level of glial fibrillary acidic protein
(Gfap), a cytoskeletal astroglial marker, was dropped down to
38% in transgenic hippocampus (Figure 6). The level of two
Gfap isoforms, Gfap-α and Gfap-σ, was also reduced to 59 and
41%, respectively, in the hippocampus of APOB-100 transgenic
mice compared to wild-type littermates (100%) (Figure 6).
Gfap immunoreactive cells displayed several processes that were
closely associated with microvessels in the cortex and in the
hippocampus too, in both experimental groups (Figure 7A).
The intensity of the fluorescent Gfap immunolabeling showed a
significant decrease in the cortex of APOB-100 transgenic mice
compared to wild-type animals (Figure 7B).
DISCUSSION
Here, we describe, that transgenic mice overexpressing the
human APOB-100 protein show chronic hypertriglyceridemia,
an increase in permeability for a small molecular marker,
and gene expressional, immunohistochemical and ultrastructural
alterations at the BBB. Several previous reports have already
shown that hypertriglyceridemia is a serious risk factor in
the development of neurodegeneration and dementia (Burgess
et al., 2006; Raffaitin et al., 2009; Bowman et al., 2012; Klafke
et al., 2015) and it was also demonstrated that dyslipidemia
is more prevalent in AD subjects with BBB impairment
(Bowman et al., 2012). Observations in aging rats, that a decrease
in cerebral blood flow is linked to pathologies similar to those
found in AD (De La Torre et al., 1992; De la Torre and
Mussivand, 1993) and demonstration of brain microvascular
injury and BBB leakage in AD patients (Zipser et al., 2007) led
to the vascular concept of AD which became generally accepted
by today (Zlokovic, 2008; Gosselet et al., 2013; Zhao et al., 2015;
Kisler et al., 2017). Lipolysis products generated from triglyceride
rich lipoproteins damage endothelial barrier function: perturb
the expression of junctional proteins, induce apoptotic cell
death in vitro in human aortic endothelial cells (Eiselein et al.,
2007) and transiently elevate BBB permeability in vivo in
mice (Lee et al., 2017). Hypertriglyceridemia may contribute
to endothelial dysfunction likely through the generation of
oxidative stress (Antonios et al., 2008). Indeed, in our recent
study (Lénárt et al., 2015) we have shown that oxidized LDL
treatment induced barrier dysfunction and increased reactive
oxygen species production and membrane rigidity in primary
brain endothelial cells.
In the present paper we studied BBB related functional and
morphological characteristics as well as gene expression profiling
of APOB-100 transgenic mice. We found APOB-100 transgenic
mice are characterized by chronic hypertriglyceridemia.
Regarding BBB function, a significantly increased extravasation
for a small molecule marker, SF, was observed in the
hippocampus of transgenic mice, which may suggest an increase
in paracellular permeability. Gene expression changes suggesting
endothelial dysfunction in APOB-100 transgenic animals include
reduced expression of the homeobox regulator Meox2, and BBB
transporters Mfsd2a, Glut1, Lrp2, Abcb1a genes in APOB-100
transgenic brain microvessels may indicate pathomechanisms
similar to those observed in conditions of BBB dysfunctions
(Zlokovic, 2011; Zhao et al., 2015). Low expression of MEOX2
was demonstrated in cultured brain endothelial cells isolated
from severely affected AD patients (Wu et al., 2005). In the same
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FIGURE 5 | Electron micrographs of brain capillaries (A) and tight junctions
(B) in the frontal cortex and hippocampus of wild-type (Wt) and APOB-100
transgenic (APOB-100) mice. Tight junctions in (B) are larger magnifications of
tight junctions seen in (A). A, astrocyte; BM, basal membrane; P, pericyte; TJ,
tight junction. Scale bars: 500 nm (A) and 800 nm (B).
study Meox2 deletion in mice resulted in decreased density of
brain capillaries, lower levels of cerebral blood flow during rest,
a diminished hypoxia-induced angiogenic response in the brain.
In addition, in these animals low levels of LRP were observed
leading to reduced Aβ eﬄux. Our observations on the drastically
reduced Meox2 in transgenic brain microvessels might also
support the link between Meox2 and neurovascular dysfunction.
Beside Meox2 the other gene for which a dramatic decrease was
observed in brain microvessels from transgenic animals was
Mfsd2a, which might have contributed to the increased BBB
permeability in our study and the neurodegeneration in our
model described previously (Bereczki et al., 2008). It has been
recently discovered, that Mfsd2a is not only a DHA transporter
at the BBB, but also a key regulator of BBB integrity and function
(Zhao and Zlokovic, 2014). Mutations in MFSD2A gene leads to
decreased DHA transport into the CNS and severe neurological
symptoms (Betsholtz, 2015), and DHA can protect cells of the
NVU against amyloid peptide toxicity (Veszelka et al., 2013). At
the BBB GLUT1 is the main transporter of glucose, the primary
energy source in the CNS. A reduction in Glut1 expression was
TABLE 1 | Summary of changes in BBB ultrastructure in the frontal cortex and
hippocampus of wild-type (Wt) and APOB-100 transgenic (APOB-100) mice.
Frontal cortex Wt APOB-100
Number of capillaries 23 33
Number of images 91 124
Capillary endothelial cell
Luminal membrane Smooth 69% 48%
Protrusions 31% 52%
Tight junctions Intact 100% 56%
Discontinuous 0% 44%
Basal membrane Intact 78% 56%
Altered 22% 44%
Pericyte
Capillary coverage 20% 17%
Capillary wo pericyte 5% 22%
Astrocyte
Intact 77% 12%
Edema 23% 88%
Hippocampus CA1 Wt APOB-100
Number of capillaries 29 30
Number of images 92 129
Capillary endothelial cell
Luminal membrane Smooth 78% 46%
Protrusions 22% 54%
Tight junctions Intact 100% 29%
Discontinuous 0% 71%
Basal membrane Intact 89% 24%
Altered 11% 76%
Pericyte
Capillary coverage 25% 23%
Capillary wo pericyte 19% 23%
Astrocyte
Intact 89% 44%
Edema 11% 56%
Values are shown as percent of all images analyzed in the group. Pericyte coverage
was calculated as written in the Materials and methods section.
linked to neurovascular dysfunction and AD in a mouse model
(Winkler et al., 2015) emphasizing the importance of the present
findings.
Additionally, the receptors Lrp1, Lrp2 and the transporter
P-gp responsible for the clearance of Aβ from the brain
(Shibata et al., 2000; Deane et al., 2003; Cirrito et al., 2005)
are downregulated in AD pathology (Marques et al., 2013). In
this study we showed a significant reduction in the expression
of the Abcb1a gene coding the P-gp isoform predominantly
expressed in brain capillary endothelial cells (Croop et al., 1989;
Shoshani et al., 1998). In agreement with this finding, the
P-gp immunolabeling could hardly be detected in APOB-100
transgenic mouse brains, which may be linked to the previously
demonstrated increased accumulation of Aβ in this model
(Bereczki et al., 2008).
A significant decrease in inducible Nos2 and endothelial
Nos3, and an increase in Lox-1 expression were detected
in microvessels isolated from APOB-100 transgenic animals.
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FIGURE 6 | Gene expression analysis of neuroinflammatory markers, transporters and Gfap isoforms in the hippocampus and cortex of APOB-100 transgenic mice.
Continuous line indicates the expression level of the corresponding gene in wild-type mice (100%). Dashed line indicates the level of significant changes: a 0.5 fold
(50%) reduction in gene expression.
TABLE 2 | Summary of gene expression changes in hypertriglyceridemic
APOB-100 transgenic mice.
mRNA Protein
Tissue Level Tissue Level
P-gp (Abcb1a) Microvessel Decreased Hippocampus Decreased
Cortex Decreased
iNOS Microvessel Decreased n.d.
eNOS Microvessel Decreased n.d.
Lox1 Microvessel Increased Cortex Increased
Aqp4 Microvessel Increased n.d
Occludin Microvessel Decreased Hippocampus No change
Cortex No change
ZO-1 Microvessel Decreased n.d
Caveolin-1 Microvessel Decreased n.d
Vimentin Microvessel Decreased Cortex Decreased
Mfsd2A Microvessel Decreased n.d
Meox-2 Microvessel Decreased n.d.
Glut-1 Microvessel Decreased n.d
Bdnf Cortex Increased n.d.
Aif-1/Iba-1 Hippocampus Increased∗ Hippocampus No change
Gfap Hippocampus Decreased Hippocampus No change
Cortex Decreased
Gfap alpha Hippocampus Decreased n.d
Gfap delta Hippocampus Decreased n.d.
IL-β Hippocampus Decreased∗ n.d
Ncadh Hippocampus Decreased n.d.
TNF-α Cortex Increased∗ n.d
NF-κB Cortex Increased∗ n.d.
Tlr4 Cortex Decreased∗ n.d
∗Denotes less than two-fold change.
The area fraction of Lox-1 immunoreactive structures was also
significantly increased in the cortex of APOB-100 transgenic mice
compared to wild-type animals. The upregulation of Lox-1 and
the downregulation of Nos2 and Nos3 mRNA levels confirmed
atherosclerotic changes in APOB-100 transgenic mice reported
earlier (Chen et al., 2002; Csont et al., 2007) The reduction in
Nos3 gene expression is in line with observations focusing on
atherosclerosis-prone regions of the mouse aorta (Won et al.,
2007) and on areas of human atherosclerosis (Buttery et al.,
1996; Barry et al., 1998). Lox-1 upregulation is observed in
atherosclerosis and linked to oxidative stress and inflammatory
reactions leading to inhibition of Nos3 enzymatic activity via
increased C-reactive protein production (Stapleton et al., 2010;
Stancel et al., 2016) and, consequently, microvessel dysfunction
in the periphery (Lubrano and Balzan, 2016). Our study suggests
for the first time, that there may be a link between neurovascular
changes and Lox-1 upregulation, Nos2 and Nos3 downregulation
in brain microvessels.
NO or NO donors at low concentrations do not modify
the barrier function of BBB culture models, while both the
blocking of basal NO production and high levels of NO
induce barrier opening (Deli et al., 2005). NO is known
to modulate cGMP-pathways which decrease resistance and
increase permeability in culture models of the BBB and may
mediate the effects of excess NO (Deli et al., 2005), but the exact
mechanisms by which NO regulates different BBB permeability
pathways are not known.
A significant decrease in Cav-1 gene expression was detected
in microvessels isolated from APOB-100 transgenic brains.
Caveolin-1 is a structural protein playing a stabilizing role
in caveolae, but it is reported to influence TJ morphology
and the expression of junctional proteins occludin and ZO-1,
too. Caveolin-1 knock-out mice are characterized by increased
paracellular permeability, smaller TJs and defects in the adhesion
of endothelial cells to the-basement membrane (Schubert et al.,
2002). Knocking down caveolin-1 expression in brain endothelial
cells resulted in a decrease in occludin and ZO-1 expression in
western blots (Song et al., 2007). However, the effect of caveolin-1
on TJ protein expression is contradictory, since an increase in
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FIGURE 7 | Gfap immunostaining pattern in the cortex and hippocampus of wild-type (Wt) and APOB-100 transgenic mice (APOB-100) (A). Scale bar: 25 µm.
Quantification of fluorescence intensity of Gfap immunolabeling in the frontal cortex and hippocampus of Wt and APOB-100 transgenic mice (B). ∗∗P < 0.01
compared with Wt mice.
caveolin-1 expression was also linked to a decrease in occludin
and or claudin-5 protein expression related to BBB damage (Nag
et al., 2007; Beauchesne et al., 2010). In our study a decrease was
observed in both caveolin-1 and occludin gene expression using
QPCR, which is in concordance with the western blot findings
reported by Song et al. (2007).
The increase in BBB permeability in our model may be
linked to reduced expression of genes coding important brain
endothelial TJ proteins Cldn-5, Ocln, Tjp-1. However, the
differences detected at mRNA level were not reflected by the
immunofluorescent staining pattern of TJ proteins claudin-5
and occludin, suggesting no detectable changes of TJs between
the experimental groups at light microscopic level. In contrast,
regarding the ultrastructure, a great percentage of discontinuous
TJs were observed in TEM images of transgenic brains. Data
obtained by PCR and immunohistochemistry do not necessarily
show direct positive correlation due to the complex regulation
of the gene expression at transcriptional, posttranscriptional,
and posttranslational levels resulting in divergences (Vogel
and Marcotte, 2012). In addition, during tissue fixation some
epitopes may suffer alterations resulting in changes in specific
antibody binding. Consequently, both these possibilities may
explain the differences between PCR data and the analysis of
immunofluorescent TJ signals.
Our findings on functional and gene expressional alterations
at the BBB in APOB-100 mice are in agreement with the
neurovascular concept of AD. Barrier dysfunction in brain
microvessels is well described in AD (Zipser et al., 2007;
Nelson et al., 2016), and BBB breakdown was found in the
hippocampus in aging human brain which may contribute to
cognitive impairment (Montagne et al., 2015).
Due to the observed similarities in gene expression changes
present in both AD pathology and in APOB-100 transgenic
mice, we examined whether neuroinflammation and neuronal
changes were also characteristic features of our model. An
increase in the gene expression of Tnfα, NF-κB and Aif-1/Iba-1
detected in the brain of APOB-100 transgenic mice suggested
inflammation related changes. Among the other inflammatory
markers examined, Tlr4, which is reported to participate in innate
neuroprotective mechanisms (Conte et al., 2017), decreased
to 60% in the cortex of APOB-100 transgenic mice. It may
indicate a disturbance in neuroprotection. Furthermore, a
significant decrease in Cdh2 expression coding N-cadherin was
observed in the hippocampus of APOB-100 transgenic animals.
N-cadherin, as an adhesion molecule, plays an important role
in connecting pericytes to endothelial cells, thus maintaining
normal BBB integrity (Winkler et al., 2011). Consequently, a
loss in N-cadherin might lead to the structural and functional
disintegration of the BBB.
The miRNA analysis revealed 10 miRNAs showing altered
expression in APOB-100 transgenic cortex compared with
wild-type ones. Out of these miRNAs mmu-miR-1a, mmu-miR-
222, mmu-miR-26a, mmu-miR-7b are correlated with validated
target genes. Among the target genes only Bdnf can be related
to neuronal changes. It is regulated by several miRNAs (Varendi
et al., 2014), among others mir-1, miRNA-26a and 26b suppress
endogenous BDNF protein levels (Caputo et al., 2011; Varendi
et al., 2014) In our study, we measured elevated Bdnf mRNA
level, while the expression level of two posttranscriptional
regulator miRNAs was changed in the opposite direction, miR-1a
was downregulated and inversely, miR-26b was upregulated.
The reduced expression of miR-1a and the increased expression
of miR-26a is in accordance with findings related to high
cholesterol levels and AD, respectively. High-cholesterol diet
induced a significant decrease of miR-1 expression in ApoE
deficient mice (Wang et al., 2013). Blocking miR-1 with
antagomir enhanced endothelial permeability, while miR-1
mimics attenuated endothelial barrier dysfunction, strongly
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FIGURE 8 | Schematic drawings showing the basic structure of the BBB (A) and highlighting the most characteristic morphological and gene expression changes
detected in cerebral microvessels of APOB-100 transgenic mice (B).
indicating that miR-1 contributes to the regulation of endothelial
barrier function (Wang et al., 2013). Similarly to our result,
miR-26a was shown to be upregulated in AD brains (Cogswell
et al., 2008) indicating that miR-26a might serve as a therapeutic
target for patients with AD (Li and Sun, 2011).
In addition to brain capillary endothelial cells and neurons,
alterations in other structural components of the NVU, such
as astrocyte endfeet and pericytes may also contribute to
BBB dysfunction. Astrocytes participate in the development
and maintenance of BBB features, including tightening of TJs,
inducing the expression of influx and eﬄux transporters, as well
as specialized enzyme systems (Deli et al., 2005; Abbott et al.,
2006; Deracinois et al., 2013). The expression level of Gfap, an
astroglia marker, is critical in maintaining BBB integrity. Either
an increase or a decrease in Gfap expression results in TJ protein
expressional changes and BBB dysfunction (Willis, 2012). The
fluorescence intensity of Gfap immunolabeling was significantly
decreased in the cortex of APOB-100 transgenic mice compared
to their wild-type littermates, which may contribute to the
observed decrease in the expression of various TJ protein coding
genes. It also may be in line with ultrastructural changes of
astrocytes, characterized by edematic swellings around capillaries
in the brain of APOB-100 transgenic mice. In a recent study
(Ito et al., 2017), an increased sodium fluorescein permeability
was reported following electroconvulsive stimulations. Regarding
brain capillary ultrastructure, intact TJs were detected in this
model of epilepsy, while astrocytic endfeet were swollen. In
another paper (Haley and Lawrence, 2017) increased BBB
permeability and astrocytic endfeet swelling occurred after
cerebral ischaemia, but TJs remained intact and TJ proteins
claudin-5 and occludin expression showed no change in
western blots. Our study is in concordance with these data
on both astroglia morphology and TJ protein expression.
The abnormalities in astrocytic endfeet may be linked to the
increased expression of Aqp4 in brain microvessels isolated from
APOB-100 transgenic animals. The loss of polarized expression
of AQP4 in astrocyte foot processes has an important impact on
development of BBB dysfunction and perivascular edema, and
also disturbed homeostasis in the brain parenchyma in various
pathologies (Wolburg et al., 2009).
S100b, another predominantly glial protein may also indicate
BBB disruption. S100B is considered a plasma biomarker in
traumatic brain injury (Halstrom et al., 2017), and cerebral
small vessel disease, in which it is associated with cognitive
impairment in patients (Gao et al., 2015). S100B is also linked to
pathological changes observed in early AD (Mattsson et al., 2014).
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In our model, no significant difference was found in S100b
gene expression in the transgenic microvessels. In contrast,
the gene expression of vimentin, another intermediate filament
protein, dropped to less than 50% in the microvessel fraction of
APOB-100 transgenic mice. The decrease in vimentin expression
was observed at protein level too, based on immunohistochemical
findings. Vimentin is expressed by endothelial cells, fibroblasts
and α-smooth muscle actin producing cells in the middle cerebral
artery of hyperlipidemic rabbits (Kacem et al., 2006). In an
attempt to identify which cell type of the NVU is producing
vimentin in our experimental animals, double immunolabeling
studies were performed. Vimentin did not colocalize either with
Gfap or Pdgfrβ, but a drop of vimentin mRNA expression
was only observed in cultured pericytes from transgenic mice.
Although cultures do not fully reflect the in vivo situation, the
immunohistochemistry data together with the vimentin QPCR
results on microvessels and cultured cells point to the possibility,
that the change in the vimentin staining in brain microvessels of
APOB-100 transgenic mice is related to pericytes. The reduction
in vimentin immunostaining in the cortical microvessels of
APOB-100 transgenic mice reflects that vimentin expression may
react very sensitively to hypertriglyceridemic conditions.
Pericytes are embedded between endothelial cells and
astrocyte endfeet in brain capillaries and they are crucial
components of the NVU. They induce the expression of
BBB-specific genes in cerebral endothelial cells and the
polarization of glial endfeet which cover brain microvessels
(Armulik et al., 2010). Pericyte deficiency leads to accelerated
amyloid angiopathy and cerebral β-amyloidosis in a mouse AD
model (Sagare et al., 2013). In our TEM analysis we detected
an increase in the ratio of capillaries displaying no pericyte
branches in the frontal cortex of APOB-100 transgenic mice
compared with wild-type animals. It may suggest a decrease in
pericyte number, which is in accordance with earlier findings
demonstrating a reduction in the number of pericytes during
neurodegeneration (Sagare et al., 2013).
CONCLUSION
In conclusion, we demonstrated here, that APOB-100 transgenic
mice are characterized by elevated serum triglyceride levels
and show functional, morphological, and gene expression
alterations suggesting BBB dysfunction (Figure 8). Based on
our findings we propose APOB-100 transgenic mice as a novel
mouse model of vascular neurodegeneration. This model might
provide researchers a useful tool to gain deeper insights into
the pathomechanism of neurodegenerative diseases of vascular
origin, which is fundamental for the development of efficient
therapies.
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